US Stock Insider Trading | Elexis disclosed one insider trading transaction on February 23

K-LinePoet · 2026-02-26T08:51:27+00:00

Exelixis recently disclosed that executive Aftab Dana sold 29,900 shares on February 19, 2026. Additionally, director Smith Julie engaged in multiple buy and sell transactions over several days. The company focuses on small molecule cancer treatments and is part of the biotechnology sector.

K-LinePoet

2026-02-26 08:51:27

Abstract generation in progress

On February 23, 2026, Exelixis (EXEL) disclosed one insider trading transaction. Executive Aftab Dana sold 29,900 shares on February 19, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Aftab Dana	February 19, 2026	Sell	29,900	44.35	1,324,900
February 20, 2026	Director	WYSZOMIERSKI JACK L	February 18, 2026	Buy	20,600	19.77	407,900
February 20, 2026	Director	WYSZOMIERSKI JACK L	February 18, 2026	Sell	99,600	44.01	4,382,300
February 19, 2026	Director	Smith Julie	February 18, 2026	Sell	44,100	44.50	1,961,900
February 19, 2026	Director	Smith Julie	February 17, 2026	Sell	42,400	43.33	1,838,100
February 19, 2026	Director	Smith Julie	February 17, 2026	Buy	42,400	18.19	771,700
February 19, 2026	Director	Smith Julie	February 18, 2026	Buy	20,000	21.69	434,500
February 19, 2026	Director	Smith Julie	February 18, 2026	Buy	44,100	19.39	854,800
February 19, 2026	Director	Smith Julie	February 18, 2026	Sell	20,000	44.30	887,300
February 18, 2026	Executive	Senner Christopher J.	February 13, 2026	Sell	34,300	43.00	1,474,000

【Company Profile】

Exelixis, Inc. is a biotechnology company dedicated to developing small-molecule cancer therapies. The company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc. in November 1994 and changed its name to Exelixis, Inc. in February 2000. The company has launched four marketed drugs, including two formulations of its flagship molecule cabozantinib. Exelixis is actively expanding its product pipeline, with its lead clinical candidate, Zanzalitin, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of colorectal cancer (CRC). The company also has a large late-stage clinical development program aimed at developing additional indications. Through a disciplined investment strategy, leveraging internal expertise and strong strategic partnerships, Exelixis seeks and capitalizes on opportunities across various scientific fields, including small-molecule drugs and biologics such as antibody-drug conjugates (ADCs).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.